Apellis Pharmaceuticals
Focus: Apellis Pharmaceuticals is a specialty pharma company headquartered in Australia, focused on complement inhibitor therapies for rare eye and kidney diseases. Now acquired by Biogen (May 2026), it operates as a mid-to-large biotech with revenue concentrated in two marketed products.
Profile data last refreshed 12h ago · AI intelligence enriched 2mo ago
Open Jobs
22
Should You Work at Apellis Pharmaceuticals?
AI assessmentApellis offers meaningful therapeutic focus and pipeline depth in complement inhibition, but post-acquisition integration risk and single-product revenue dependency warrant careful evaluation of role stability and long-term career trajectory within Biogen.
Why Work Here
- Strong marketed products with EMPAVELI (pegcetacoplan) generating $25M Part D spending at peak lifecycle, providing revenue stability through 2038 LOE.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$25M Part DStable
Peak12.2yr
Flagship complement inhibitor driving 94% of company revenue; faces competition but maintains market presence through 2038.
Help build intelligence for Apellis Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.